Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coherus BioSciences, Inc. (Exact ...

JUPITER-06: A Randomized, Double-blind, Phase 3 Study of Toripalimab versus Placebo In Combination with First-Line Chemotherapy for Treatment Naive Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) R.-H. Xu1, F. Wang1, C. Cui2, J. Yao3, Y. Zhang4, G. Wang5, J. Feng6, S. Yang7, Y. Fan8, J. Shi9, X.Zhang10, L. Shen11, Y.Shu12, C. Wang13, T. Dai14, T. Mao15, L. Chen16, Z. Guo17, B. Liu18, H. Pan19, Coherus Biosciences and Shanghai Junshi Biosciences. 1Department of Medical Oncology, Sun Yat-Sen ...

Coherus BioSciences August 2021 Copyright ©2021 All Rights Reserved. Forward Looking Statements Except for the historical information contained herein, the matters set forth in this primer are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the risk that the parties are unable to obtain clearance under the Hart-Scott Rodino Antitrust Improvements Act, from the Committee on Foreign Investment ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q2 2021 Earnings Conference Call August 5, 2021 5:00 PM ET Company Participants McDavid Stilwell - CFO Dennis Lanfear - CEO Paul Reider - EVP, Commercial Operations and Market Access Chris Thompson - EVP, Sales Conference Call Participants Douglas Tsao - H.C. Wainwright Salim Syed - Mizuho Chris Schott - JPMorgan Operator Good day and thank you for standing by. Welcome to the Quarter 2, 2021 Coherus Conference Call. At this time, all participants are in a listen-only ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coherus BioSciences, Inc. (Exact name ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2021 Earnings Conference Call May 5, 2021 4:30 PM ET Company Participants McDavid Stilwell - CFO Dennis Lanfear - CEO Paul Reider - EVP, Commercial Operations and Market Access Chris Thompson - EVP, Sales Shah Rahimian - SVP, Immuno-Oncology Clinical Development Conference Call Participants Mohit Bansal - Citi Jason Gerberry - Bank of America Chris Schott - JPMorgan Benet Gresely - Mizuho Georgi Yordanov - Cowen & Company Gregg Gilbert - Truist Securities Douglas T ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coherus BioSciences, Inc. (Exact name ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2020 Earnings Conference Call February 24, 2021 4:30 PM ET Company Participants McDavid Stilwell - EVP of Corporate Development; IR and Financial Strategy Denny Lanfear - CEO Jean Viret - CFO Vincent Anicetti - Chief Operating Officer Chris Thompson - EVP, Sales Conference Call Participants Chris Schott - JPMorgan Mohit Bansal - Citigroup Salim Syed - Mizuho Securities Balaji Prasad - Barclays Jason Gerberry - Bank of America Greg Gilbert - Truist Securities George ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share CHRS The Nasdaq Global Market Securities Registered Pursuant to Section 12(g) of the Act: None UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year end ...

| --- | --- | |-------|-------| | | | | | | | | | Copyright ©2021 All Rights Reserved. Forward Looking Statements Except for the historical information contained herein, the matters set forth in this primer are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Coherus' potential market opportunity for its biosimilar product candidates, if approved; plans to file the BLA for Bioeq's biosimilar ...